CLINUVEL Showcases Afamelanotide Peptide for Vitiligo at AAD 2026, Phase III Fully Enrolled
CLINUVEL presented afamelanotide (Scenesse) vitiligo data at the American Academy of Dermatology annual meeting to 20,000+ delegates. The Phase III CUV105 trial has completed enrollment of 200+ patients across 3 continents. Clinical cases showed repigmentation after 20 weeks maintained through 6-month follow-up, even in patients with active disease. Topline results expected H2 2026.